These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 24465544)
1. Association between polymorphisms in XRCC1 gene and treatment outcomes of patients with advanced gastric cancer: a systematic review and meta-analysis. Cao Z; Song J; Wang J; Guo X; Yu S; Dong W PLoS One; 2014; 9(1):e85357. PubMed ID: 24465544 [TBL] [Abstract][Full Text] [Related]
2. Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis. Cui Z; Yin Z; Li X; Wu W; Guan P; Zhou B BMC Cancer; 2012 Feb; 12():71. PubMed ID: 22339849 [TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic role of XRCC1 polymorphisms on the clinical outcome of gastric cancer patients with platinum-based chemotherapy: a systematic review and meta-analysis. Xu J; Ma J; Zong HT; Wang SY; Zhou JW Genet Mol Res; 2014 Mar; 13(1):1438-46. PubMed ID: 24634242 [TBL] [Abstract][Full Text] [Related]
4. X-ray repair cross-complementing 1 polymorphism and prognosis of platinum-based chemotherapy in gastric and colorectal cancer: a meta-analysis. Wu H; Xu C; Chen G; Wang J J Gastroenterol Hepatol; 2014 May; 29(5):926-33. PubMed ID: 24224851 [TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis. Li L; Wan C; Wen FQ Genet Mol Res; 2014 May; 13(2):3772-86. PubMed ID: 24938464 [TBL] [Abstract][Full Text] [Related]
6. XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis. Zhang X; Jiang LP; Yin Y; Wang YD Tumour Biol; 2014 Jun; 35(6):5637-45. PubMed ID: 24590266 [TBL] [Abstract][Full Text] [Related]
7. No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy. Yuan P; Liu L; Wu C; Zhong R; Yu D; Wu J; Xu Y; Nie S; Miao X; Sun Y; Xu B; Lin D Cancer Biol Ther; 2010 Nov; 10(9):854-9. PubMed ID: 20814250 [TBL] [Abstract][Full Text] [Related]
8. X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms and gastric cancer risk: A HuGE review and meta-analysis. Xue H; Ni P; Lin B; Xu H; Huang G Am J Epidemiol; 2011 Feb; 173(4):363-75. PubMed ID: 21216841 [TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic Association between Zhang N; Ouyang Y; Chang J; Liu P; Tian X; Yu J Biomed Res Int; 2020; 2020():3520764. PubMed ID: 33150172 [TBL] [Abstract][Full Text] [Related]
10. Association of X-ray repair cross-complementing group 1 Arg194Trp, Arg399Gln and Arg280His polymorphisms with head and neck cancer susceptibility: a meta-analysis. Wu W; Liu L; Yin Z; Guan P; Li X; Zhou B PLoS One; 2014; 9(1):e86798. PubMed ID: 24497981 [TBL] [Abstract][Full Text] [Related]
11. Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement. Li DJ; Xiao D BMC Cancer; 2017 Jul; 17(1):501. PubMed ID: 28743242 [TBL] [Abstract][Full Text] [Related]
12. Associations between XRCC1 Gene Polymorphisms and Coronary Artery Disease: A Meta-Analysis. Ma WQ; Han XQ; Wang X; Wang Y; Zhu Y; Liu NF PLoS One; 2016; 11(11):e0166961. PubMed ID: 27870881 [TBL] [Abstract][Full Text] [Related]
13. Association of XRCC1 Arg399Gln and Arg194Trp polymorphisms with susceptibility to multiple autoimmune diseases: a meta-analysis. Peng M; Zhou X; Ding X; Wei L; Zhao Y; Zhu T; Shi X; Qin D Rheumatol Int; 2017 Mar; 37(3):435-444. PubMed ID: 27812739 [TBL] [Abstract][Full Text] [Related]
14. Variant Alleles in XRCC1 Arg194Trp and Arg399Gln Polymorphisms Increase Risk of Gastrointestinal Cancer in Sabah, North Borneo. Halim NH; Chong ET; Goh LP; Chuah JA; See EU; Chua KH; Lee PC Asian Pac J Cancer Prev; 2016; 17(4):1925-31. PubMed ID: 27221877 [TBL] [Abstract][Full Text] [Related]
15. XRCC1 Arg399Gln, Arg194Trp, and Arg280His polymorphisms in esophageal cancer risk: a meta-analysis. Li S; Deng Y; You JP; Chen ZP; Peng QL; Huang XM; Lu QH; Huang XL; Zhao JM; Qin X Dig Dis Sci; 2013 Jul; 58(7):1880-90. PubMed ID: 23543084 [TBL] [Abstract][Full Text] [Related]
16. Role of GSTP1 Ile105Val and XRCC1 Arg194Trp, Arg280His and Arg399Gln gene polymorphisms in the clinical outcome of advanced non-small cell lung cancer. Zhao R; Chen G Int J Clin Exp Pathol; 2015; 8(11):14909-16. PubMed ID: 26823821 [TBL] [Abstract][Full Text] [Related]
17. XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy: A systematic review and MOOSE-compliant meta-analysis. Zhang Z; Xiang Q; Mu G; Xie Q; Chen S; Zhou S; Hu K; Cui YM Medicine (Baltimore); 2018 Nov; 97(45):e12996. PubMed ID: 30407287 [TBL] [Abstract][Full Text] [Related]
18. XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population. Wang Z; Xu B; Lin D; Tan W; Leaw S; Hong X; Hu X Lung Cancer; 2008 Oct; 62(1):99-104. PubMed ID: 18400332 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy: A PRISMA-compliant meta-analysis. Lv Y; Xu M; Sun Y; Liu Y; Zhao L; Liu X; Li Z; Shi G; Jia J; Bi L; Ma N; Zhang X; Qi C Medicine (Baltimore); 2021 Aug; 100(33):e26850. PubMed ID: 34414935 [TBL] [Abstract][Full Text] [Related]
20. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies. Chen J; Zhao QW; Shi GM; Wang LR J Zhejiang Univ Sci B; 2012 Nov; 13(11):875-83. PubMed ID: 23125080 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]